2024
Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry
Lebwohl M, Strober B, Schrader A, Li A, Eckmann T, Zhu B, Malatestinic W, Birt J, Feely M, Blauvelt A. Six-Month Real-World Study to Assess the Effectiveness of Ixekizumab After Switching from IL-23 Inhibitors and Other Biologic Therapies: The CorEvitas Psoriasis Registry. Drugs - Real World Outcomes 2024, 1-14. PMID: 38914857, DOI: 10.1007/s40801-024-00439-w.Peer-Reviewed Original ResearchTumor necrosis factor inhibitorsInvestigator's Global AssessmentEffectiveness of ixekizumabDermatology Life Quality IndexDermatology Life Quality Index 0/1Body surface areaIL-23iCorEvitas Psoriasis RegistryIL-12/23iPatient-reported outcomesIL-17iPsoriasis RegistryBiologic therapySkin painSwitching to ixekizumabIL-23 inhibitorsDisease severityInterleukin-23 inhibitorAdjusted mean changesMultivariable modified Poisson regressionInterleukin-12/23 inhibitorsFollow-up visitConfidence intervalsModified Poisson regressionReal-world study
2021
POS1032 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
Mease P, Lertratanakul A, Strober B, Tsuji S, Richette P, Lovan C, Feng D, Anderson J, Van den Bosch F. POS1032 EFFICACY OF UPADACITINIB IN PATIENTS WITH PSORIATIC ARTHRITIS STRATIFIED BY NUMBER OF PRIOR BIOLOGIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS. Annals Of The Rheumatic Diseases 2021, 80: 788-789. DOI: 10.1136/annrheumdis-2021-eular.564.Peer-Reviewed Original ResearchMinimal disease activityBiologic DMARDsOverall study populationInadequate responseAbbVie Inc.Boehringer IngelheimSpeakers bureauClinical trialsStudy populationEli LillyConsistent efficacyBristol-MyersFirst-line anti-TNF therapyDisease-modifying anti-rheumatic drugsSF-36 physical component summaryAnti-TNF therapyComprehensive disease controlPrior inadequate responseSubgroups of ptsThird-line therapyAnti-rheumatic drugsInvestigator's Global AssessmentSanofi-AventisPhysical component summaryConfidence intervals
2017
Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study
Papp K, Bachelez H, Costanzo A, Foley P, Gooderham M, Kaur P, Narbutt J, Philipp S, Spelman L, Weglowska J, Zhang N, Strober B. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. Journal Of The American Academy Of Dermatology 2017, 76: 1093-1102. PMID: 28291552, DOI: 10.1016/j.jaad.2016.12.014.Peer-Reviewed Original ResearchConceptsABP 501Week 16Psoriasis AreaClinical similaritiesBiosimilar ABP 501Biosimilars of adalimumabSevere plaque psoriasisDouble-blind studySeverity Index scoreTreatment of patientsAntibody incidencePlaque psoriasisSevere psoriasisAdalimumabIndex scoreEquivalence marginPatientsImmunogenicityConfidence intervalsTreatment differencesPercent improvementPsoriasisSame treatmentBaselineMore improvement
2013
SAT0267 Safety of Ustekinumab from the Placebo-Controlled Periods of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs
McInnes I, Papp K, Puig L, Reich K, Ritchlin C, Strober B, Rahman P, Kavanaugh A, Mendelsohn A, Song M, Chan D, Shen Y, Li S, Gottlieb A. SAT0267 Safety of Ustekinumab from the Placebo-Controlled Periods of Psoriatic Arthritis and Psoriasis Clinical Developmental Programs. Annals Of The Rheumatic Diseases 2013, 72: a673. DOI: 10.1136/annrheumdis-2013-eular.1992.Peer-Reviewed Original ResearchGrant/research supportPsA populationOverall safety ratePsO/PsASafety event rateRates of AEsHigh rateActive PsA.Pt-yrRelevant comorbiditiesMedian durationPASI scorePsoriatic arthritisSkin involvementConcurrent therapyBSA involvementMedical historyFamily historySafety rateOverall AEEvent ratesPSAConfidence intervalsSimilar proportionsResearch support